Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1016/s2213-2600(19)30247-4

Type

Journal

The Lancet. Respiratory medicine

Publication Date

10/2019

Volume

7

Pages

834 - 835

Addresses

Medical Research Council Clinical Trials Unit, University College London, London, UK; Institute for Global Health, University College London, London, UK; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: h.esmail@ucl.ac.uk.

Keywords

Humans, Mycobacterium tuberculosis, Tuberculosis, Pulmonary, Ethambutol, Isoniazid, Pyrazinamide, Rifampin, Antitubercular Agents, Drug Therapy, Combination, Microbial Sensitivity Tests, Drug Resistance, Microbial, Precision Medicine